

# MaxCyte

16:42 24 Apr 2019

## MaxCyte looks ahead to "pivotal" 2019 with demand for its cell engineering platform on the rise

MaxCyte Inc (LON:MXCT) is looking ahead to a "pivotal year" as demand for its cell engineering technology booms.

Revenues swelled by 19% to US\$16.7m last year (2017: US\$14.0m), driven by deals with the likes of CRISPR Therapeutics and Gilead-owned Kite to use its Flow Electroporation software.

**READ:** MaxCyte fighting cancer battle on two fronts

Flow Electroporation is used in gene editing and allows almost any molecule - such as DNA, RNA or proteins - to be delivered into any cell with minimal cell disturbance.

The top-line boost helped underlying losses narrow to US\$0.8m in 2018, down from US\$1.2m a year earlier.

That figure excludes a US\$6.5m investment into CARMA - MaxCyte's cell therapy platform which it is using to develop drug candidates that harness the immune system to attack tumours.

The first drug from that platform, MCY-M11, began a Phase I study last year and is being used to treat 15 women with ovarian cancer and peritoneal mesothelioma, which forms around the tissue lining of the womb.

MaxCyte hopes this first study will help to validate and establish CARMA, and a second trial is earmarked to get underway later in 2019.

The company finished the year with US\$14.4m of cash in the bank, although a US\$12.9m (£10.0m) fundraise last month will have topped up the coffers even further.

At the forefront of a growing sector

"Our core markets, cell therapy and immuno-oncology, continue to expand rapidly as do applications for gene-editing technologies in the development of various therapies for the treatment of inherited genetic diseases and a number of cancers," said chief executive Doug Doerfler.

"MaxCyte has established itself as a world leader in non-viral cell engineering - offering a rapid and efficient means of delivering the future generation of cell-based therapies, which is underlined by recent commercial and research partnerships with leading biotech companies including Kite."

He added: "This is a very exciting time for the Company and our team, and we expect 2019 to be a pivotal year for MaxCyte."

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts

**Price:** £1.22

**Market Cap:** £70.01 m

### 1 Year Share Price Graph



September 2018 May 2019 September 2019

### Share Information

**Code:** MXCT

**Listing:** AIM

**52 week High Low**  
238.5 100

**Sector:** Pharma & Biotech

**Website:** [www.maxcyte.com](http://www.maxcyte.com)

### Company Synopsis:

*We are a U. S. -based global company driving the acceleration of the discovery/development, manufacturing and commercialization of next-generation, cell-based medicines.*

action@proactiveinvestors.com.au

journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of MaxCyte named herein, including the promotion by the Company of MaxCyte in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).